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Abstract  
Objective: We aimed to re-examine mortality risk estimates for metabolically healthy obesity by 
using a ‘stable’ healthy non-obese referent group.  
Design: prospective cohort study 
Methods: Participants were 5,427 men and women (aged 65.9 ± 9.4 years, 45.9% men) from the 
English Longitudinal Study of Ageing. Obesity was defined as body mass index ≥ 30 kg/m
2 
(vs. non-
obese as below this threshold). Based on blood pressure, HDL-cholesterol, triglycerides, glycated 
haemoglobin, and C-reactive protein, participants were classified as ‘healthy’ (0 or 1 metabolic 
abnormality) or ‘unhealthy’ (≥ 2 metabolic abnormalities).   
Results: 671 deaths were observed over an average follow up of 8 years. When defining the referent 
group based on 1 clinical assessment, the unhealthy non-obese (Hazard ratio = 1.22; 95% CI, 1.01, 
1.45) and unhealthy obese (1.29; 1.05, 1.60) were at greater risk of all-cause mortality compared to 
the healthy non-obese, yet no excess risk was seen in the healthy obese (1.14; 0.83, 1.52). When we 
re-defined the referent group based on 2 clinical assessments, effect estimates were accentuated 
and healthy obesity was at increased risk of mortality (2.67; 1.64, 4.34).  
Conclusion: An unstable healthy referent group may make ‘healthy obesity’ appear less harmful by 
obscuring the benefits of remaining never obese without metabolic dysfunction.  
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Introduction  
Termed ‘metabolically healthy obesity’, population based studies have identified an obesity 
phenotype that is not accompanied by a clustering of adiposity associated cardio-metabolic 
risk factors [1]. Although tendencies for metabolic decline and for developing type 2 
diabetes are becoming clear [1], associations of healthy obesity with outcomes related to 
cardiovascular disease and mortality are less consistent [2,3]. One explanation for these 
inconsistencies may be differences in the duration of follow-up used across studies, with 
those using shorter follow-up times tending to find no association between healthy obesity 
and outcomes [4,5]. Some studies have considered instability of healthy obesity itself as 
another potential explanation [6-8]; yet little-to-no attention has focused on the importance 
of the group to which healthy obesity is being compared, usually defined as some form of 
‘healthy non-obese’.  
Studies that examine the risks of healthy obesity tend to rely on one-off measures of body 
mass index and biomarkers of metabolic health. As a consequence, estimates of excess 
disease risk among healthy obese versus healthy non-obese adults may be obscured in at 
least two ways; one, by failing to distinguish those obese individuals who have been obese 
for many years from those who have only recently gained enough weight to become obese; 
and two, by failing to distinguish referent non-obese individuals who have had a body mass 
index (BMI) below the obese range for many years from those who only recently became 
obese or who used to be obese but had lost weight. These same obscurities would apply to 
markers of metabolic health, although these are known to track closely with changes in BMI, 
even within the strictly normal-weight range [9]. 
Page 3 of 22
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
4 
 
This study aimed to improve risk estimates for mortality among healthy obese adults by 
examining associations using a stable healthy non-obese referent group defined from repeat 
biomedical assessments.
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Materials and Methods 
Study sample and procedures 
The English Longitudinal Study of Ageing (ELSA) is an ongoing cohort study that contains a 
nationally representative sample of free-living men and women born on or before 29 
February 1952 [10]. Data collected in 2004-05 were used as the baseline for present 
analyses, as this was the first occasion clinical data were measured objectively by a nurse. 
An identical clinical assessment was repeated 4 years later (2008-09). Individual participant 
data were linked with death records from National Health Service registries for all 
consenting respondents (96.5% of the sample) up to February 2012. Participants gave full 
informed written consent to participate in the study and ethical approval was obtained from 
the London Multi-Centre Research Ethics Committee.  
Clinical Measurements  
Nurses collected anthropometric data (weight, height), blood pressure (BP), and non-fasting 
blood samples using standard protocols. Body weight was measured without shoes and in 
light clothing using Tanita electronic scales, and height was measured using a stadiometer 
with the Frankfort plane in the horizontal position. Body mass index (BMI) was calculated as 
weight (kilograms)/height (meters) squared. Systolic and diastolic BP was measured with an 
Omron HEM-907 blood pressure monitor three times in the sitting position after 5-minute 
rest between each reading. The initial reading was discarded and an average of the second 
and third BP recordings was used for the present analyses. Blood samples were analyzed for 
high sensitivity C-reactive protein (CRP), high density lipoprotein (HDL) cholesterol, 
triglycerides, and glycated haemoglobin (HbA1c). Detailed information on the technicalities 
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of the blood analysis, the internal quality control, and the external quality assessment for 
the laboratory have been described elsewhere [11]. Additional data were collected on 
physician diagnosed conditions (hypertension, diabetes) and medication use. 
Covariates at baseline 
Age and sex were recorded in 2004-05. Ethnicity was not considered as the sample was 
ethnically homogenous (93.9%% white-British).  Health behaviours included cigarette 
smoking (current, previous or non-smoker), the frequency of participation in light, 
moderate, and vigorous physical activities (more than once per week, once per week, one to 
three times per month, hardly ever), any reported chronic illness, and depressive symptoms 
(a score of 3 or higher out of 8 on the 8-item Centre of Epidemiological Studies Depression 
scale [12]). Wealth was used as a measure of socioeconomic status, as this has been shown 
to best capture the material resources available to older adults [13]. Wealth was calculated 
as net of debt and included the total value of the participant’s home (excluding mortgage), 
financial assets such as savings, business assets, and physical wealth such as artwork or 
jewelry. 
Statistical analyses 
We used conventional criteria to define obesity (BMI ≥ 30 kg/m
2
). Underweight participants 
(BMI<18.5 kg/m
2
) were excluded to prevent possible reverse causation (as underweight is 
often a marker of serious illness in older adults). A healthy metabolic status was based on 
independently proposed criteria [14], and according to availability of data, defined as having 
less than 2 of the following 5 metabolic risk factors: high BP (BP ≥130/85 mmHg, or 
hypertension diagnosis, or use of anti-hypertensive medication), impaired glycaemic control 
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(HbA1c > 6.0% [42.1 mmol/mol] or doctor’s diagnosed diabetes), systemic inflammation 
(CRP≥ 3mg/l), low HDL cholesterol (<1.03 mmol/l in men and <1.30 mmol/l in women), and 
high triacylglycerol (≥ 1.7 mmol/l). Participants were then categorized into 1 of 4 groups:  
‘healthy non-obese’; ‘unhealthy non-obese’; ‘healthy obese ’; and ‘unhealthy obese’. We 
used Cox proportional hazards regression models to examine associations between 
metabolic-BMI group and mortality, with healthy non-obese based on the 2004-05 
assessment. Age at death was recorded and years were the time scale for the follow-up. For 
consenting participants with no record of an event, the data were censored at February 
2012. The proportional hazards assumption was examined by using plots of the Nelson-
Aalen cumulative hazard estimates. We estimated models that were initially adjusted for 
age and sex. The final models were additionally adjusted for physical activity, smoking, 
depressive symptoms (CES-D>3), chronic illness, wealth.  These covariates were selected a 
priori based on previous literature [4,6,8]. These analyses were repeated with the healthy 
non-obese referent group refined to include only participants who met criteria for a healthy 
status and were non-obese in both 2004-05 and 2008-09. All other participants remained 
assigned to their baseline categories, and those from the original referent category that 
transitioned into unhealthy/obese groups (n=515) or did not provide data at follow up 
(n=994) were removed. Deaths in the first 4 years of follow up were removed in order to 
retain consistency with the new referent category. All models were repeated in sensitivity 
analyses using a more stringent definition of metabolic health, defined as having 0 of 5 risk 
factors. A two-sided p-value of 0.05 was used to indicate statistical significance. All analyses 
were conducted using SPSS version 22 (SPSS, Chicago, IL). 
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Results  
A total of 8,688 participants (82% of participants at the first point of contact in 2002-03) 
attended the clinical assessment in 2004-05.  The present study reports only on those that 
consented and were eligible and able to give blood (n=5903); this excluded men and women 
with clotting and bleeding disorders, or taking anti-coagulant medication. After excluding 79 
participants that did not provide consent to linkage of mortality records, and a further 397 
because of missing data, the final analytic sample comprised 5,427 men and women (aged 
65.9 ± 9.4 years, 45.9% men).  
 Descriptive characteristics of the sample are displayed in Table 1. Around 46.0% of the 
sample were characterised as ‘healthy non-obese’; 25.2% as ‘unhealthy non-obese’; 9.5% as 
‘healthy obese ’; and 19.3% as ‘unhealthy obese’. The healthy non-obese were generally 
wealthier than other participants and displayed better health behaviour including higher 
physical activity levels, fewer depressive symptoms and chronic illnesses.  
A total of 671 deaths were observed over an average follow up of 8 years. In covariate 
adjusted models that defined the healthy non-obese referent group based on 2004-05 only 
(Table 2), the unhealthy non-obese (Hazard ratio; 95% CI = 1.22; 1.01, 1.45), and unhealthy 
obese (1.29; 1.05, 1.60) were at greater risk of mortality, although no excess risk was 
observed in the healthy obese (1.14; 0.83, 1.52). A similar pattern emerged for death from 
cardiovascular diseases (CVD) although significant excess risk remained only among the 
unhealthy obese in the final model. Medication (including anti-hypertensive, lipid lowering, 
and diabetes medications) was used in 35.9% of the cohort at baseline. The results were not 
substantially different after controlling for medication use (Table S1). 
Page 8 of 22
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
9 
 
During 4 years of follow up, 65.8% of healthy non-obese participants remained stable in this 
category (Table S2). In covariate adjusted models that re-defined the healthy non-obese 
referent group based on data from both 2004-05 and 2008-09 effect estimates for mortality 
were accentuated in the unhealthy non-obese and obese groups, and the healthy obese 
were also at increased risk (2.67; 1.64, 4.34) (Table 3). 
In sensitivity analyses we used the more stringent definition of metabolic health (based on 0 
of 5 risk factors) although results remained largely unchanged (Table S3). Our original 
criterion for metabolic health was based on the clinically valid CRP threshold of 3 mg/l [15]. 
We also re-defined metabolic health using the 90th percentile for CRP (8.2 mg/l in our 
sample), as used by others [14], although the results were not substantially changed (Table 
S4).
Page 9 of 22
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
10 
 
Discussion  
The aim of this study was to examine associations between metabolically healthy obesity 
phenotype and mortality. Unlike previous studies we defined the healthy non-obese 
referent category from repeated biomedical assessments in order to ensure risk among 
healthy obese adults was compared with adults who remained never obese without 
metabolic risk factors over an extended period of time. Using this refined referent category, 
our results suggest that  excess risk of mortality among unhealthy non-obese and unhealthy 
obese groups are greater than previously thought, and that risk is indeed elevated among 
the healthy obese.  
Previous studies [2-5] had defined the referent category (‘healthy non-obese’) based on 
clinical assessments made at a single point in time, thus potentially making ‘healthy obesity’ 
appear less harmful by making comparisons with a group that is heterogeneous with respect 
to obesity exposure. Indeed, an unstable referent category may create bias in several ways,   
such as through containing individuals who were recently obese but had lost weight due to 
the onset of disease. This issue is still possible in the groups as defined in our study, for 
example, if adults with very high BMI lost weight in response to disease yet still fell within 
the obese range of BMI. The number of individuals with very high BMI, however, was small 
in our sample (7.5% of obese above BMI 40 kg/m
2
); most were just above the obesity 
threshold of 30 kg/m
2
 (72.5 % of the obese being between 30-35 kg/m
2
). Nevertheless, the 
older age of participants in the present study remains a limitation, given that associations 
between BMI and mortality risk are more prone to reverse causation by way of subclinical 
disease-induced weight loss than are such associations when examined among younger 
adults [16].  
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The few studies that have made use of multiple observations of BMI over the life course to 
study disease outcomes suggest that each additional observation enhances predictive value, 
with future morbidity being a positive function of the duration of obesity [17-21]. This has 
been recently applied within the ‘healthy obesity’ paradigm to demonstrate that greater 
duration of obesity was associated with higher likelihood of developing the metabolic 
syndrome [22].  
 This study has its limitations. We were only able to utilise biomedical data from two visits as 
weight histories prior to baseline were not available. Given a lack of consensus for the 
definition of metabolically healthy obesity, we defined metabolic health using an adaptation 
of previous criteria [14] according to availability of data. The decision to use a categorization 
of 0 or 1 metabolic risk factor to define a metabolically healthy status was to allow for 
consistency with previous work [14] and for clinical relevance. Sensitivity analyses using a 
more stringent definition based on zero metabolic risk factors to define metabolic health 
produced similar results, yet were necessarily based on smaller numbers of participants 
given that most ‘healthy’ obese adults present with 1 risk factor. 
In conclusion, using repeat biomedical assessments in order to define a referent group that 
remained never obese without metabolic risk factors for an extended period of time, our 
results suggest that the risk of mortality is far greater among unhealthy non-obese and 
unhealthy obese adults than previously thought, and is indeed elevated among the healthy 
obese. Previous studies may have underestimated the detrimental effects of ‘healthy 
obesity’ by obscuring the benefits of remaining never obese without metabolic risk factors.
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Table 1. Baseline characteristics of the sample (n=5,427). 
 Metabolically 
healthy  
non-obese 
(n=2503) 
Metabolically 
unhealthy non-
obese 
(n=1364) 
Metabolically 
healthy  
obese 
 (n=514) 
Metabolically 
unhealthy 
obese  
(n=1046) 
Age (yrs) 65.5±9.5 67.7±9.6 64.3±8.8
 
65.6±9.0 
Men (%) 44.6 52.5  43.8
 
41.4 
Depressive symptoms (% 
CES-D>3) 
11.6 14.3 13.2
 
16.6 
Longstanding illness (%) 44.2 58.3 46.9 65.0 
Current smokers (%) 14.1  20.7  9.9
 
16.3 
Vigorous physical activity (% 
at least once/wk) 
37.0 26.4 28.4
 
20.7 
Lowest wealth quintile (%) 10.6 15.2 13.4 21.6 
Body mass index (kg/m
2
) 25.1±2.7 26.4±2.4 32.8±2.9
 
34.1±3.9 
HDL cholesterol (mmol/l) 1.67±0.37 1.37±0.36 1.54±0.30
 
1.34±0.32 
Triglycerides (mmol/l) 1.37±0.71 2.28±1.06 1.54±0.73
 
2.42±1.74 
HbA1c (%) 5.39±0.38 5.77±0.86 5.47±0.41
 
5.95±0.95 
C-reactive protein (mg/l) 1.93±3.41 5.11±7.73 2.90±4.48
 
6.26±7.59 
Systolic BP (mmHg) 130.5±17.1 139.5±18.7 135.8±15.8
 
140.5±18.3 
Diastolic BP (mmHg) 73.2±9.8 76.2±11.9 75.9±8.6
 
79.1±11.6 
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Table 2. Cox proportional hazards regression for associations of obesity, metabolic health and 
mortality, with referent healthy non-obese group defined by status in 2004-05 only (n=5,427). 
Baseline metabolic 
health/obesity status 
All Deaths / N Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Healthy non-obese  262/2503 1.00 (ref) 1.00 (ref) 
Unhealthy non-obese 215/1364 1.35 (1.12, 1.61) 1.22 (1.01, 1.45) 
Healthy obese 52/514 1.20 (0.89, 1.62) 1.14 (0.83, 1.52) 
Unhealthy obese 142/1046 1.51 (1.23, 1.86) 1.29 (1.05, 1.60) 
 
 CVD deaths/N   
Healthy non-obese 62/2503 1.00 (ref) 1.00 (ref) 
Unhealthy non-obese 54/1364 1.43 (1.00, 2.06) 1.29 (0.89, 1.87) 
Healthy obese 9/514 0.98 (0.49, 1.97) 0.92 (0.45, 1.86) 
Unhealthy obese 38/1046 1.91 (1.27, 2.88) 1.57 (1.03, 2.40) 
Model 1 adjusted for age and sex 
Model 2 adjusted for age, sex, wealth, physical activity, smoking, depressive symptoms, chronic 
illness. 
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Table 3. Cox proportional hazards regression for associations of obesity, metabolic health and 
mortality, with referent healthy non-obese group based on status in both 2004-05 and 2008-09 
(n=3,868). 
Baseline metabolic 
health/obesity status  
All Deathsⱡ / N Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Stable healthy non-obese† 27/992 1.00 (ref) 1.00 (ref) 
Unhealthy non-obese 186/1335 3.52 (2.34, 5.28) 2.99 (1.98, 4.52) 
Healthy obese 43/505 2.98 (1.84, 4.83) 2.67 (1.64, 4.34) 
Unhealthy obese 132/1036 4.20 (2.78, 6.36) 3.50 (2.28, 5.35) 
    
 CVD deaths/N   
Stable healthy non-obese† 5/992 1.00 (ref) 1.00 (ref) 
Unhealthy non-obese 47/1335 4.15 (1.64, 10.49) 3.64 (1.42, 9.33) 
Healthy obese 5/505 1.79 (0.52, 6.19) 1.55 (0.44, 5.42) 
Unhealthy obese 35/1036 5.78 (2.26, 14.78) 4.67 (1.78, 12.22) 
Model 1 adjusted for age and sex 
Model 2 adjusted for age, sex, wealth, physical activity, smoking, depressive symptoms, chronic 
illness. 
† Reference group contains par3cipants that remained metabolically healthy non-obese over four 
years follow up. Participants from referent category that transitioned into unhealthy groups (n=515) 
or did not provide data at follow up (n=994) were removed. 
ⱡ Deaths from first 4 years of follow up removed in order to retain consistency with referent 
category. 
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Supplementary analyses 
Table S1. Cox proportional hazards regression for associations of obesity, metabolic health and 
mortality, with referent healthy non-obese group defined by status in 2004-05 only (n=5,427). 
Models additionally adjusted for medication. 
Baseline metabolic 
health/obesity status 
All Deaths / N Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Healthy non-obese  262/2503 1.00 (ref) 1.00 (ref) 
Unhealthy non-obese 215/1364 1.35 (1.12, 1.61) 1.31 (1.08, 1.58) 
Healthy obese 52/514 1.20 (0.89, 1.62) 1.17 (0.86, 1.58) 
Unhealthy obese 142/1046 1.51 (1.23, 1.86) 1.38 (1.11, 1.71) 
 
 CVD deaths/N   
Healthy non-obese 62/2503 1.00 (ref) 1.00 (ref) 
Unhealthy non-obese 54/1364 1.43 (1.00, 2.06) 1.40 (0.95, 2.06) 
Healthy obese 9/514 0.98 (0.49, 1.97) 0.95 (0.47, 1.93) 
Unhealthy obese 38/1046 1.91 (1.27, 2.88) 1.68 (1.09, 2.59) 
Model 1 adjusted for age and sex 
Model 2 adjusted for age, sex, wealth, physical activity, smoking, depressive symptoms, chronic 
illness, medication (lipid lowering, anti-hypertensive, diabetes medication). 
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Table S2. Change in metabolic health/obesity status over 4 years 
Baseline 4- year follow-up Total 
MHNO MUNO MHO MUO 
 MHNO 994 406 49 60 1509 
MUNO 185 499 7 73 764 
MHO 25 19 107 129 280 
MUO 16 46 58 417 537 
Total 1220 970 221 679 3090 
Healthy non-obese (MHNO) ; unhealthy non-obese (MUNO); Healthy obese (MHO); Unhealthy obese 
(MUO) 
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Table S3. Cox proportional hazards regression for associations of obesity, metabolic health and 
mortality: sensitivity analyses using zero risk factors to define ‘metabolically healthy’ and referent 
healthy non-obese group based on 2004-05 only (n=5,427). 
Baseline metabolic 
health/obesity status 
All Deaths / N Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Healthy non-obese 90/1155 1.00 (ref) 1.00 (ref) 
Unhealthy non-obese 387/2712 1.61 (1.28, 2.02) 1.49 (1.18, 1.87) 
Healthy obese 14/142 1.46 (0.83, 2.57) 1.39 (0.79, 2.44) 
Unhealthy obese 156/1348 1.73 (1.33, 2.25) 1.49 (1.14, 1.95) 
 
 CVD deaths/N   
Healthy non-obese 15/1155 1.00 (ref) 1.00 (ref) 
Unhealthy non-obese 101/2712 2.60 (1.51, 4.47) 2.42 (1.40, 4.19) 
Healthy obese 4/142 2.70 (0.89, 8.12) 2.63 (0.87, 7.98) 
Unhealthy obese 37/1348 2.90 (1.58, 5.34) 2.46 (1.33, 4.56) 
Model 1 adjusted for age and sex 
Model 2 adjusted for age, sex, wealth, physical activity, smoking, depressive symptoms, chronic 
illness. 
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Table S4. Cox proportional hazards regression for associations of obesity, metabolic health and 
mortality, with referent healthy non-obese group defined by status in 2004-05 only (n=5,427). 
Categories re-defined using modified criteria (90
th
 percentile) for C-reactive protein. 
Baseline metabolic 
health/obesity status 
All Deaths / N Model 1 
HR (95% CI) 
Model 2 
HR (95% CI) 
Healthy non-obese  300/2876 1.00 (ref) 1.00 (ref) 
Unhealthy non-obese 177/1085 1.35 (1.16, 1.64) 1.31 (1.07, 1.59) 
Healthy obese 71/728 1.18 (0.91, 1.53) 1.13 (0.87, 1.47) 
Unhealthy obese 99/794 1.44 (1.15, 1.81) 1.31 (1.03, 1.67) 
 
 CVD deaths/N   
Healthy non-obese 73/2876 1.00 (ref) 1.00 (ref) 
Unhealthy non-obese 43/1085 1.33 (0.91, 1.94) 1.40 (0.95, 2.06) 
Healthy obese 14/728 1.08 (0.61, 1.92) 0.95 (0.47, 1.93) 
Unhealthy obese 27/794 1.84 (1.18, 2.88) 1.68 (1.09, 2.59) 
Model 1 adjusted for age and sex 
Model 2 adjusted for age, sex, wealth, physical activity, smoking, depressive symptoms, chronic 
illness, medication (lipid lowering, anti-hypertensive, diabetes medication). 
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